Thrombolytic microspheres to dissolve vaso-occlusive clots
OwnerRichard C.K. Yeninventor
Life of this patent
Estimating the term…
Abstract
A product, composition, suspension and/or method to treat subjects infected with respiratory viruses, such as coronavirus, and in relieving hypoxic condition. A suspension of thrombolytic albumin nanospheres that can target vaso-occlusive clots in vivo and then lyse the obstructive blood clots with high efficiency can be intravenously administer to a subject in need thereof. The nanospheres can encapsulate an enzymatically active bioreactive agent, such as urokinase. Since the active enzyme is targeting and binding essentially only to obstructive clots, there is minimal risk of side-effects to the subject. The nanospheres are less than one micron in diameter, resulting in a size much smaller than red blood cells.
Claims20
A thrombolytic microsphere to dissolve vaso-occlusive clots comprising a submicron albumin sphere, and an enzymatically active bioreactive agent encapsulated in the albumin sphere, wherein the albumin sphere being configured to dissolve vaso-occlusive clots in vivo.
A composition for dissolving vaso-occlusive clots in a subject in need thereof, the composition comprising a therapeutically effective amount of an albumin nanoparticle suspension containing submicron albumin spheres, and an enzymatically active bioreactive agent encapsulated in the albumin spheres, wherein the albumin spheres being configured to dissolve vaso-occlusive clots in vivo.
A method of dissolving vaso-occlusive clots in a subject in need thereof, the method comprising the steps of administering a therapeutically effective amount of an albumin nanoparticle suspension containing submicron albumin spheres, and an enzymatically active bioreactive agent encapsulated in the albumin spheres to the subject, wherein the albumin spheres being configured to dissolve vaso-occlusive clots in vivo.
Dependencies are inferred from the claim text.